ClinicalTrials.gg
CompletedNCT01627327Updated Nov 9, 2017Results posted

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease

A Phase 3 interventional study of fluticasone furoate/vilanterol 100/25mcg and tiotropium bromide 18mcg in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 55 sites in 6 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-11-09.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
623
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline — 7 open to participants now, 8 under way, 5 of them phase 3. Pulmonary Disease, Chronic Obstructive · GlaxoSmithKline.

Enrollment
45th of 236
623 · median 101
Started
2012
with 16 others
Phase 3
65 of 276
5 open now
Registered
150th of 276
by date

Among the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, this one is the 45th largest by enrollment of the 236 interventional ones that give a count, is one of 17 that started in 2012, is one of 65 in phase 3, and was the 150th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

7 of the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg once daily compared with tiotropium bromide inhalation powder 18mcg once daily over a 12-week treatment period in subjects with COPD who have or are at risk for co-morbid cardiovascular disease

Read the detailed description

This is a randomized, double-blind, double-dummy, multi-center, parallel-group study. Subjects who meet the eligibility criteria at Screening and at the end of a 2-week Run-In Period will enter a 12-week Treatment Period. There will be a 7-day Follow-up Period after the Treatment Period.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive

Keywords

  • Cardiovascular event
  • Cardiovascular disease
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated written
  • Male or females ≥ 40 years of age
  • Females must be or using a highly effective method for avoidance of pregnancy
  • Established clinical history of by ATS/ERS definition
  • Post-albuterol spirometry criteria: /FVC ratio ≤ 0.70 and FEV1 ≥30 to ≤ 70% of predicted normal (NHANES III)
  • Former or current smoker ≥10 pack years
  • A history of diagnosed cardiovascular disease or a prior cardiovascular event including any of the following:
  • Established (i.e., by clinical signs or imaging studies) coronary artery disease (CAD)
  • Established (i.e., by clinical signs or imaging studies) peripheral vascular (i.e., arterial) disease (PVD)
  • Previous stroke
  • Objectively confirmed (TIA) (i.e., transient neurological deficit documented by a health-care professional)
  • Previous myocardial infarction (MI) (Note: An MI within 6 months prior to Visit 1 is exclusionary)

OR

  • Presence of one of the following cardiovascular risk factors (in addition to being a former/current smoker):
  • Current diagnosis of hypertension
  • Current diagnosis of hypercholesterolemia
  • Diabetes mellitus treated with pharmacotherapy

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of asthma
  • Subjects with other respiratory disorders including α1-antitrypsin deficiency as the underlying cause of , active tuberculosis, lung cancer, bronchiectasis (Note: focal bronchiectasis is not exclusionary), sarcoidosis, pulmonary fibrosis (Note: focal fibrotic pulmonary lesions are not exclusionary), pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases
  • Lung volume reduction surgery within previous 12 months
  • abnormalities not due to COPD by chest X-ray or CT scan
  • Hospitalized for poorly controlled COPD within 12 weeks of Screening
  • Poorly controlled COPD 6 weeks prior to Screening, defined as acute worsening of COPD that is managed by the subject with or antibiotics or that requires treatment prescribed by a physician
  • Lower respiratory infection requiring antibiotics 6 weeks prior to Screening
  • A moderate or severe COPD exacerbation and/or a lower respiratory tract infection (including pnuemonia) during the Run-In Period
  • An abnormal, clinically significant finding in any liver chemistry, biochemical, or haematology tests at Screening (Visit 1) or upon repeat prior to randomization
  • An abnormal, clinically significant finding at Screening (Visit 1) or upon repeat prior to randomization
  • An abnormal, clinically significant Holter finding at Screening (Visit 1) or upon repeat prior to randomization (sub-set of subjects)
  • Historical or current evidence of clinically significant (in opinion of the Investigator) and unstable disease such as cardiovascular (e.g., patients requiring ICD, pacemaker requiring a ventricular pace rate set at >60 bpm, uncontrolled hypertension, Class IV (New York Heart Association,1994), known \<30%), neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease), peptic ulcer disease, or haematological abnormalities
  • Carcinoma not in complete remission for at least 5 years
  • History of allergy or to any of the study medications (e.g., anticholinergic/muscarinic receptor antagonist, beta2-agonist, corticosteroid) or components of the inhalation powder (e.g., lactose, magnesium stearate) or a medical condition such as narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the study physician contraindicates study participation or use of an inhaled anticholinergic. In addition, subjects with a history of severe milk protein allergy that, in the opinion of the Investigator, contraindicates the subject's participation will also be excluded
  • Known/suspected history of alcohol or drug abuse in the last 2 years
  • Women who are pregnant or lactating or plan to become pregnant
  • Subjects medically unable to withhold albuterol /salbutamol for 4 hours prior to spirometry testing at each study visit
  • Use of certain medications such as bronchodilators and corticosteroids for the protocol-specific times prior to Visit 1 (the Investigator will discuss the specific medications)
  • Long Term Oxygen Therapy (LTOT) or nocturnal oxygen therapy >12 hours a day
  • Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Screening or during the study
  • Failure to demonstrate adequate compliance defined as completion of the Diary Card (completed all diary entries on at least 4 of the last 7 consecutive days), the ability to withhold COPD medications and to keep clinic visit appointments
  • Non-compliance or inability to comply with study procedures or scheduled visits
  • History of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of to participate in the study
  • Affiliation with investigator site
  • Women who are pregnant or lactating or are planning on becoming pregnant during the study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
623 participants (actual)

Study arms

  • Experimental
    fluticasone furoate/vilanterol

    inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA)

    Drug: fluticasone furoate/vilanterol 100/25mcg

  • Active comparator
    tiotropium bromide

    anticholinergic

    Drug: tiotropium bromide 18mcg

Interventions

  • Drugfluticasone furoate/vilanterol 100/25mcg

    inhalation powder

  • inhalation powder

    Also known as: Spiriva

06

What researchers measure

Primary outcomes

  1. Change From Baseline Trough in 24-hour Weighted Mean FEV1 on Treatment Day 84

    Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled from the lungs in one second. The weighted mean was calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, 30 minutes and 1, 2, 4, 6, 8, 12, 13, 14, 16, 20, and 24 hours on Treatment Day 84. Baseline trough FEV1 was the mean of the two assessments made 30 and 5 minutes pre-dose on Treatment Day 1. Change from Baseline (BL) was calculated as the average of the Day 84 values minus the Baseline value. Analysis was performed using an analysis of covariance (ANCOVA) model with covariates of BL FEV1, exacerbation history and reversibility stratum, smoking status at screening, country, and treatment group.

    Time frame: Baseline and Day 84

Secondary outcomes

  1. Time to Onset on Treatment Day 1

    Time to onset on Treatment Day 1 is defined as the time to an increase of 100 milliliters (mL) from Baseline in FEV1. Time of onset was calculated over 0 to 4 hours (5 minutes (min), 15 min, 30 min, 60 min, 120 min, and 240 min) post-dose. Time to onset was analyzed using a log-rank test, stratified by exacerbation history and reversibility stratum.

    Time frame: Baseline and Day 1

  2. Change From Baseline in Trough FEV1 at Treatment Day 84

    Pulmonary function was measured by FEV1. Trough FEV1 was defined as the 24-hour FEV1 assessment, which was obtained on Day 84. Baseline is defined as the mean of the two assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1.Change from Baseline was calculated as the average of the Day 84 values minus the Baseline value. Analysis was performed using an ANCOVA model with covariates of BL FEV1, exacerbation history and reversibility stratum, smoking status at screening, country, and treatment group.

    Time frame: Baseline and Day 84

07

Results

Posted Nov 1, 2013

Participant flow

Participant flow — Overall Study
MilestoneFF/VI 100/25 µg ODTIO 18 µg OD
Started310313
Completed291274
Not completed1939
Withdrew: Adverse event612
Withdrew: Lack of efficacy-no sub-reason02
Withdrew: Lack of efficacy-sub-reason exacerbation49
Withdrew: Protocol violation410
Withdrew: Lost to follow-up13
Withdrew: Physician decision10
Withdrew: Withdrawal by subject33

Outcome measures

PrimaryChange From Baseline Trough in 24-hour Weighted Mean FEV1 on Treatment Day 84

Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled from the lungs in one second. The weighted mean was calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, 30 minutes and 1, 2, 4, 6, 8, 12, 13, 14, 16, 20, and 24 hours on Treatment Day 84. Baseline trough FEV1 was the mean of the two assessments made 30 and 5 minutes pre-dose on Treatment Day 1. Change from Baseline (BL) was calculated as the average of the Day 84 values minus the Baseline value. Analysis was performed using an analysis of covariance (ANCOVA) model with covariates of BL FEV1, exacerbation history and reversibility stratum, smoking status at screening, country, and treatment group.

Time frame:
Baseline and Day 84
Reported as:
Least squares mean · Liters
Change From Baseline Trough in 24-hour Weighted Mean FEV1 on Treatment Day 84
LitersFF/VI 100/25 µg ODTIO 18 µg OD
Change From Baseline Trough in 24-hour Weighted Mean FEV1 on Treatment Day 840.117 ± 0.01300.095 ± 0.0138
Statistical analysis
  • FF/VI 100/25 µg OD vs TIO 18 µg OD · ANCOVA · p = 0.201 · Median difference (net): 0.022 · 95% CI -0.012 to 0.055
SecondaryTime to Onset on Treatment Day 1

Time to onset on Treatment Day 1 is defined as the time to an increase of 100 milliliters (mL) from Baseline in FEV1. Time of onset was calculated over 0 to 4 hours (5 minutes (min), 15 min, 30 min, 60 min, 120 min, and 240 min) post-dose. Time to onset was analyzed using a log-rank test, stratified by exacerbation history and reversibility stratum.

Time frame:
Baseline and Day 1
Reported as:
Median · Minutes
Time to Onset on Treatment Day 1
MinutesFF/VI 100/25 µg ODTIO 18 µg OD
Time to Onset on Treatment Day 117.0 (5 to 240)20.5 (5 to 240)
SecondaryChange From Baseline in Trough FEV1 at Treatment Day 84

Pulmonary function was measured by FEV1. Trough FEV1 was defined as the 24-hour FEV1 assessment, which was obtained on Day 84. Baseline is defined as the mean of the two assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1.Change from Baseline was calculated as the average of the Day 84 values minus the Baseline value. Analysis was performed using an ANCOVA model with covariates of BL FEV1, exacerbation history and reversibility stratum, smoking status at screening, country, and treatment group.

Time frame:
Baseline and Day 84
Reported as:
Least squares mean · Liters
Change From Baseline in Trough FEV1 at Treatment Day 84
LitersFF/VI 100/25 µg ODTIO 18 µg OD
Change From Baseline in Trough FEV1 at Treatment Day 840.098 ± 0.01330.093 ± 0.0140

Adverse events

Collected over On-Treatment serious adverse events (SAEs) and non-serious AEs were collected from the start of study medication until Follow-up (up to 13 weeks).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FF/VI 100/25 µg OD—10/310 (3.2%)31/310 (10%)
TIO 18 µg OD—10/313 (3.2%)32/313 (10.2%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventFF/VI 100/25 µg ODTIO 18 µg OD
PneumoniaInfections and infestations3/3100/313
Urinary tract infectionInfections and infestations2/3100/313
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders2/3101/313
Cardio-respiratory arrestCardiac disorders0/3102/313
Post procedural infectionInfections and infestations1/3100/313
Anaemia postoperativeInjury, poisoning and procedural complications1/3100/313
Patella fractureInjury, poisoning and procedural complications1/3100/313
Blood pressure fluctuationVascular disorders1/3100/313
ThrombosisVascular disorders1/3100/313
Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/3100/313
Most frequent other events
Most frequent other events
EventFF/VI 100/25 µg ODTIO 18 µg OD
HeadacheNervous system disorders18/31023/313
NasopharyngitisInfections and infestations16/31013/313

Baseline characteristics

Age, Continuous
Age, Continuous(Years)FF/VI 100/25 µg ODTIO 18 µg ODTotal
Mean62.9 ± 8.0962.3 ± 7.9862.6 ± 8.03
Sex: Female, Male
Sex: Female, Male(Participants)FF/VI 100/25 µg ODTIO 18 µg ODTotal
Female117104221
Male193209402
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)FF/VI 100/25 µg ODTIO 18 µg ODTotal
African American/African Heritage8715
Asian - East Asian Heritage011
White - White/Caucasian/European Heritage302305607
08

Study locations

55 sites
  • GSK Investigational Site
    Newport Beach, California 92663, United States
  • GSK Investigational Site
    Coeur d'Alene, Idaho 83814, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28207, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45231, United States
  • GSK Investigational Site
    Medford, Oregon 97404, United States
  • GSK Investigational Site
    Gaffney, South Carolina 29340, United States
  • GSK Investigational Site
    Greenville, South Carolina 29615, United States
  • GSK Investigational Site
    Seneca, South Carolina 29678, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States
  • GSK Investigational Site
    Union, South Carolina 29379, United States
  • GSK Investigational Site
    Newport News, Virginia 23606, United States
  • GSK Investigational Site
    Winnipeg, Manitoba R2H 2A6, Canada
  • GSK Investigational Site
    Truro, Nova Scotia B2N 1L2, Canada
  • GSK Investigational Site
    Toronto, Ontario M5V 2T3, Canada
  • GSK Investigational Site
    Montreal, Quebec H2W 1T8, Canada
  • GSK Investigational Site
    Montreal, Quebec H4J 1C5, Canada
  • GSK Investigational Site
    Montreal, Quebec H4N 3C5, Canada
  • GSK Investigational Site
    Sherbrooke, Quebec J1H 1Z1, Canada
  • GSK Investigational Site
    St-Charles-Borromée, Quebec J6E 2B4, Canada
  • GSK Investigational Site
    St-Romuald, Quebec G6W 5M6, Canada
  • GSK Investigational Site
    Kralupy nad Vltavou, 278 01, Czechia
  • GSK Investigational Site
    Kromeriz, 767 55, Czechia
  • GSK Investigational Site
    Teplice, 415 10, Czechia
  • GSK Investigational Site
    Trebic, 674 01, Czechia
  • GSK Investigational Site
    Zamberk, 564 01, Czechia
  • GSK Investigational Site
    Cottbus, Brandenburg 03050, Germany
  • GSK Investigational Site
    Ruedersdorf, Brandenburg 15562, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60596, Germany
  • GSK Investigational Site
    Neu-Isenburg, Hessen 63263, Germany
  • GSK Investigational Site
    Schwerin, Mecklenburg-Vorpommern 19055, Germany
  • GSK Investigational Site
    Magdeburg, Sachsen-Anhalt 39112, Germany
  • GSK Investigational Site
    Dresden, Sachsen 01069, Germany
  • GSK Investigational Site
    Leipzg, Sachsen 04109, Germany
  • GSK Investigational Site
    Grosshansdorf, Schleswig-Holstein 22927, Germany
  • GSK Investigational Site
    Berlin, 10117, Germany
  • GSK Investigational Site
    Berlin, 10717, Germany
  • GSK Investigational Site
    Berlin, 10787, Germany
  • GSK Investigational Site
    Berlin, 10789, Germany
  • GSK Investigational Site
    Bialystok, Poland
  • GSK Investigational Site
    Czestochowa, 42-200, Poland
  • GSK Investigational Site
    Dzialdowo, 13-200, Poland
  • GSK Investigational Site
    Krakow, 31-024, Poland
  • GSK Investigational Site
    Piekary Slaskie, 41-940, Poland
  • GSK Investigational Site
    Slupsk, 76-200, Poland
  • GSK Investigational Site
    Tarnow, 33-100, Poland
  • GSK Investigational Site
    Bucharest, 020125, Romania
  • GSK Investigational Site
    Bucharest, 030317, Romania
  • GSK Investigational Site
    Bucharest, 050159, Romania
  • GSK Investigational Site
    Bucuresti, 70000, Romania
  • GSK Investigational Site
    Cluj Napoca, 400371, Romania
  • GSK Investigational Site
    Cluj-Napoca, 400371, Romania
  • GSK Investigational Site
    Constanta, 900002, Romania
  • GSK Investigational Site
    Iasi, 700115, Romania
  • GSK Investigational Site
    Suceava, 720284, Romania
  • GSK Investigational Site
    Timisoara, 300310, Romania
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2013, 11 months after primary completion. A results delay was requested in Jun 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2012
First posted
Jun 25, 2012
Start
Apr 1, 2012
Primary completionActual
Dec 1, 2012
CompletionActual
Dec 21, 2012
Results delay requested
Jun 20, 2013
Results first posted
Nov 1, 2013
Last update
Nov 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01627327
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 25, 2012
Start date
Apr 1, 2012
Primary completion
Dec 1, 2012
Completion
Dec 21, 2012
Results posted
Nov 1, 2013
Last update
Nov 9, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion